• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

    9/9/25 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLRB alert in real time by email

    Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25

    Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM

    Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Triple-Negative Breast Cancer in 4Q25

    FLORHAM PARK, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Company management will participate at the upcoming Oppenheimer 3rd Annual Targeted Radiopharmaceuticals in Oncology Summit taking place on September 11, 2025, in New York City.

    While participating at this radiopharmaceutical therapy summit, Cellectar management will be meeting with investors and discussing the Company's progress in recent months and future plans, including, among other topics:

    • Progress with the European Medicines Agency's (EMA) regarding scientific advice on the company's continued preparation for a potential Conditional Market Authorization (CMA) submission.
      • Provided data to EMA data from the Phase 2b CLOVER WaM clinical trial where the company observed a statistically significant major response rate, meaningful duration of response and integrated summary of safety for all patients treated with iopofosine I 131 for hematologic malignancies.
      • A follow-up meeting with the EMA was completed and a final decision from the EMA on their recommendation whether to submit for a CMA is expected in late third quarter or early fourth quarter 2025.
    • Plans to pursue a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the accelerated approval of iopofosine I 131 as a treatment for Waldenstrom's Macroglobulinemia (WM), subject to raising sufficient additional funding and once the confirmatory trial is underway.
      • The submission would be supported by data from the Phase 2b CLOVER WaM clinical trial demonstrating a statistically significant major response rate compared to a null hypothesis of 20% and meaningful duration of response. The data set now includes the FDA-requested 12-month follow-up results on all patients from the trial and new subset analysis of data from patients immediately following Bruton Tyrosine Kinase inhibitor (BTKi) treatment failures regardless of line of therapy.
      • The Company plans to share these new data at an upcoming medical or scientific conference.
    • Initiation of Phase 1b Dose Finding study of the company's Auger-emitting radiopharmaceutical, CLR 125, for the treatment of relapsed triple-negative breast cancer (TNBC), planned for the fourth quarter 2025. CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative breast, lung and colorectal cancers.
    • Execution of long-term multi-isotope supply agreements to provide Cellectar with iodine-125 and actinium-225 to support its clinical studies and future commercial needs.

    "We recently completed our scheduled meeting with the EMA and remain hopeful that the agency will recommend that we file for a fast track, conditional marketing authorization approval and expect their decision in the near term. As previously stated, we remain in active partnering discussions seeking capital to support global regulatory requirements and the potential worldwide marketing of iopofosine I 131," said Jim Caruso, president and chief executive officer of Cellectar. "Additionally, we continue to make strong progress with our novel phospholipid drug conjugate pipeline and are excited to advance our lead auger-emitting asset, CLR 125, into our planned Phase 1b trial for the treatment of TNBC in the fourth quarter of this year."

    About Cellectar Biosciences, Inc.

    Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

    The company's product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225 (CLR 225), an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

    In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.

    For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company's social media channels: X, LinkedIn, and Facebook.

    Forward Looking Statements Disclaimer

    This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarterly period ending June 30, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

    INVESTORS:

    Anne Marie Fields

    Precision AQ

    212-362-1200

    [email protected]



    Primary Logo

    Get the next $CLRB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLRB

    DatePrice TargetRatingAnalyst
    12/5/2024$13.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $CLRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:02:08 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Longcor Jarrod bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 361% to 12,768 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:01:18 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Kolean Chad J bought $24,950 worth of shares (5,000 units at $4.99), increasing direct ownership by 353% to 6,418 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:00:13 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target

    Ladenburg Thalmann resumed coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $13.00

    12/5/24 8:32:15 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cellectar Biosciences Inc.

    SCHEDULE 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    8/14/25 6:12:37 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)

    8/14/25 7:30:37 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cellectar Biosciences Inc.

    10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)

    8/14/25 7:07:35 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

    Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Triple-Negative Breast Cancer in 4Q25 FLORHAM PARK, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and developmen

    9/9/25 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

    FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September. Details are as follows: ADC and Novel Conjugates Partnering and Investment Summit Title:ADCs x Radioligands: The Use of One Technology to Advance the OtherDate/Time:September 9, 2025, 9:30 AM ET BioProcess International Title:ADCs and Beyond in RadiopharmaceuticalsD

    9/5/25 8:45:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

    FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company's novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma. "We are excited to present our poster a

    9/3/25 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:02:08 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Longcor Jarrod bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 361% to 12,768 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:01:18 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Kolean Chad J bought $24,950 worth of shares (5,000 units at $4.99), increasing direct ownership by 353% to 6,418 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:00:13 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Financials

    Live finance-specific insights

    View All

    Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025 On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and dev

    8/14/25 7:19:07 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

    FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, August 14, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:94699Webcast:Click HERE   A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations we

    8/7/25 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update on its promising portfolio of clinical and pre-clini

    5/13/25 7:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

    William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "

    10/17/23 8:00:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

    ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

    3/27/23 4:05:00 PM ET
    $CLRB
    $MXCT
    $REXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Major Pharmaceuticals

    $CLRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    11/14/24 4:47:59 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    11/14/24 1:26:20 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    8/14/24 7:15:55 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care